FTC orders divestiture based on harm to suppliers
The Federal Trade Commission has cleared global healthcare company Grifols to buy Biotest on the condition that it sells certain assets, after raising concerns about harm to the market for the supply of blood as well as the sale of hepatitis B immune globulin.
Subscribe to Global Competition Review
Subscribe and start reading now
Already have access? Login below
Copyright © Law Business ResearchCompany Number: 03281866 VAT: GB 160 7529 10